Childhood cancers trials in South Korea
64 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Where
- Seoul
- People
- 64 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT06590857 - Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Jongno-gu, Songpa-gu
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 3Taking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Daegu, Goyang-si, Gyeonggi-do, Seoul
- Age
- 15 years and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Seoul
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 2Taking peopleA Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 12 years to 17 years
- People
- 15 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07700758 · EU 2025-524515-37-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Busan, Jeollanam, Seoul, Uijeongbu-si
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 1/2Taking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Goyang-si, Seoul
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - Phase 3Taking peopleA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Where
- Goyang-si, Gyeonggi-do, Seongnam-si, Seoul
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00 - Phase 1/2Taking peopleA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
- Where
- Seoul
- Age
- 6 months to 30 years
- People
- 65 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05533775 - Phase 1/2Taking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Seoul
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - Phase 2/3Taking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Seoul
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - No phaseTaking peopleDevelopment and Utilization of an Integrated Clinical Genomic Database
- Where
- Seoul
- People
- 118,750
- Run by
- Samsung Medical Center
See details and how to joinNCT07911267 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 1/2Taking peopleA Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Where
- Seoul
- Age
- 1 month to 17 years
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07630974 · EU 2025-522339-32-00 - Phase 1/2Taking peopleStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- Where
- Seoul
- Age
- 16 years and over
- People
- 85 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00 - No phaseTaking peopleA Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
- Where
- Daejeon, Goyang-si, Hwasun Gun, Seoul, Suwon, Uijeongbu-si, Yangsan
- People
- 377
- Run by
- Astellas Pharma Korea, Inc.
See details and how to joinNCT06902545 - Phase 3Taking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Busan, Daegu, Goyang-si, Seoul
- Age
- 12 years and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - No phaseTaking peopleA Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- Where
- Busan, Daegu, Daejeon, Goyang-si, Incheon, Jeollanam-do, Jeonju, Seoul, Suwon
- People
- 228
- Run by
- Astellas Pharma Korea, Inc.
See details and how to joinNCT06011954 - No phaseTaking peopleTreatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
- Where
- Goyang-si, Seoul
- Age
- 12 years and over
- People
- 400
- Run by
- MedPacto, Inc.
See details and how to joinNCT07878364 - Phase 1/2Taking peopleStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Where
- Seoul
- Age
- 12 years and over
- People
- 83 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00 - Phase 1/2Taking peopleSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
- Where
- Seoul
- Age
- 1 year to 30 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07387926 - Phase 2Taking peopleONO-4538 Phase II Rollover Study (ONO-4538-98)
- Where
- Daegu, Gyeonggi-do, Hwasun, Incheon, Seoul, Suwon
- Age
- 16 years and over
- People
- 70 worldwide
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT04566380 - Phase 1/2Taking peopleAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Where
- Seoul
- Age
- 12 years and over
- People
- 255 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00 - Phase 1/2Taking peopleAZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Where
- Seoul
- Age
- 12 years and over
- People
- 161 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06137144 · EU 2023-506747-42-00 - No phaseTaking peopleProspective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV
- Where
- Seoul
- People
- 2,000
- Run by
- Samsung Medical Center
See details and how to joinNCT07032103